Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
IB Ventures, also known as Innovation Booster, is a venture capital firm established in 2025, headquartered in Riyadh, Saudi Arabia, with additional offices in Switzerland and the United States. The firm is recognized as Saudi Arabia's first dedicated biotech VC fund, focusing on early-stage investments in the biotech sector. This includes areas such as therapeutics, diagnostics, digital biology, and biomanufacturing. IB Ventures aims to align its operations with Saudi Arabia's Vision 2030, which emphasizes innovation and the growth of the biotech industry, projected to significantly contribute to the national economy.
The firm manages a fund size of $50 million and is committed to enhancing the local biotech landscape by attracting global innovations and nurturing local talent. IB Ventures is strategically positioned to support the Kingdom's ambitions in the biotech sector, which is expected to play a crucial role in diversifying the economy and creating jobs.
IB Ventures primarily invests in early-stage biotech startups, providing both capital and strategic support. The firm focuses on sectors such as therapeutics, diagnostics, digital biology, and biomanufacturing. The check size typically aligns with early-stage funding rounds, although specific ranges are not disclosed. IB Ventures emphasizes the importance of business development, commercialization, and scaling operations for its portfolio companies.
The organization is dedicated to nurturing local talent while also attracting global biotech innovations to Saudi Arabia. This dual approach enhances the country's position in the global biotech landscape. IB Ventures seeks founders who demonstrate a strong vision and capability to execute their business plans, particularly in the biotech domain. The firm also values project feasibility and tailors strategies for business growth, ensuring that startups are well-prepared for success in a competitive market.
IB Ventures has invested in a diverse range of biotech and related companies, totaling eight notable portfolio companies. These include:
Antonio Fabrizio: Founder of IB Ventures, Antonio has extensive experience in the biotech sector and has been instrumental in establishing the firm as a leader in early-stage biotech investments.
Dr. Hamad Al Omar: Co-founder and Managing Partner, Dr. Al Omar brings a wealth of knowledge in biotechnology and has a strong background in healthcare innovation.
Dr. Yazeed Al Sufyani: Co-founder and Managing Partner, Dr. Al Sufyani is recognized for his contributions to the biotech field and has participated in various international biotech conferences, including BIO-Europe 2025.
Faisal Al-Abdulsalam: General Partner at IB Ventures, Faisal has a strong track record in venture capital and business development, focusing on scaling biotech startups.
Mohammed Alangari: General Partner, Mohammed has expertise in operational management and strategic planning within the biotech industry.
To pitch IB Ventures, founders should use the contact email info@ib.ventures or the website www.ib.ventures. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. Founders should expect a response within a few weeks, although timelines may vary based on the volume of inquiries.
Warm introductions are preferred but not mandatory. A clear and concise presentation of the startup's vision and potential impact in the biotech sector will enhance the chances of securing a meeting with the investment team.
In April 2026, IB Ventures officially launched its $50 million fund aimed at driving biotech innovation in Saudi Arabia. This launch positions the firm as a key player in the Kingdom's efforts to enhance its biotech sector under Vision 2030.
IB Ventures has made headlines for its commitment to supporting local biotech startups and attracting global innovations. The firm is expected to play a significant role in the development of the biotech industry in Saudi Arabia, contributing to the national economy.
What investment criteria does IB Ventures use?
IB Ventures focuses on early-stage biotech startups, particularly in therapeutics, diagnostics, digital biology, and biomanufacturing. They look for innovative solutions that align with their strategic goals and the broader objectives of Saudi Arabia's Vision 2030.
How can I apply or pitch to IB Ventures?
Founders can pitch to IB Ventures through their website at www.ib.ventures or via email at info@ib.ventures. It is advisable to include a detailed business plan and an overview of the technology or product being developed.
What makes IB Ventures different from other VCs?
IB Ventures is unique as it is the first dedicated biotech VC fund in Saudi Arabia, focusing on supporting local talent and attracting global innovations. The firm provides not only capital but also strategic support in business development and commercialization.
What is the geographic scope of IB Ventures?
IB Ventures primarily targets biotech startups in Saudi Arabia and the broader region, while also looking to import global biotech innovations into the Kingdom.
What is the fund size and check size range?
IB Ventures manages a fund size of $50 million. While specific check sizes are not disclosed, the firm is expected to lead pre-seed, seed, and Series A rounds, typically ranging from $1 million to $5 million based on industry standards.
What kind of post-investment involvement can founders expect?
IB Ventures provides tailored support to its portfolio companies, including assistance with go-to-market strategies, fundraising, and mergers and acquisitions. The firm emphasizes project feasibility analysis and creates customized strategies for business growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.